MARKET

ALIM

ALIM

Alimera Sciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.47
-0.20
-2.07%
Closed 16:00 05/10 EDT
OPEN
9.78
PREV CLOSE
9.67
HIGH
9.78
LOW
9.31
VOLUME
16.53K
TURNOVER
--
52 WEEK HIGH
12.25
52 WEEK LOW
3.821
MARKET CAP
65.33M
P/E (TTM)
-6.5623
1D
5D
1M
3M
1Y
5Y
Diabetic Retinopathy Market 2020-25: Global Trends, Share, Industry Analysis And Forecast Report
May 07, 2021 (SUPER MARKET RESEARCH via COMTEX) -- According to the latest report by IMARC Group, titled "Diabetic Retinopathy Market: Industry Trends,...
SUPER MARKET RESEARCH · 3d ago
Global Diabetic Macular Edema Treatment Market Size, Share, Value, and Competitive Landscape 2021-2026
May 05, 2021 (Heraldkeepers) -- The Diabetic Macular Edema Treatment market report provides a detailed analysis of global market size, regional and...
Heraldkeepers · 5d ago
Global Tunnel Boring Machine Market Size 2021 Research Findings, Market Growth Factors Analysis and Forecasts – 2026
May 03, 2021 (The Expresswire) -- In 2021 ,,Tunnel Boring Machine Market :- A tunnel boring machine (TBM) is a machine used to excavate tunnels with a...
The Express Wire · 05/03 05:54
DJ Alimera Sciences Inc. CEO Rick Eiswirth on Q1 2021 Results -- Earnings Call Transcript >ALIM
Dow Jones · 05/01 20:18
Analysts Offer Insights on Healthcare Companies: Alimera (ALIM) and BioMarin Pharmaceutical (BMRN)
SmarterAnalyst · 04/30 10:35
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28)
Benzinga · 04/29 12:15
Alimera Sciences, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / April 29, 2021 / Alimera Sciences, Inc. (NASDAQ:ALIM) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on April 29, 2021 at 9:00 AM Eastern Time.
ACCESSWIRE · 04/29 11:45
What are The Major Factors Expected to Limit The Growth Of The Ocular Inflammation Treatment Market?
Apr 29, 2021 (Heraldkeepers) -- The Ocular Inflammation Treatment Market is expected to exceed more than US$ 500 Billion by 2024 at a CAGR of 6% in the given...
Heraldkeepers · 04/29 07:55
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALIM. Analyze the recent business situations of Alimera Sciences through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALIM stock price target is 16.38 with a high estimate of 18.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 51
Institutional Holdings: 31.41M
% Owned: 455.32%
Shares Outstanding: 6.90M
TypeInstitutionsShares
Increased
6
469.90K
New
2
504.61K
Decreased
1
86.64K
Sold Out
4
484.56K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.20%
Pharmaceuticals & Medical Research
-0.44%
Key Executives
Non-Executive Chairman
C. Daniel Myers
President/Chief Executive Officer/Director
Richard Eiswirth
Chief Financial Officer
Phil Jones
Chief Operating Officer/Senior Vice President
Philip Ashman
Senior Vice President/Chief Marketing Officer
David Holland
Other
Samer Kaba
Lead Director/Independent Director
James Largent
Independent Director
Brian Halak
Independent Director
Garheng Kong
Independent Director
Peter Pizzo
Independent Director
John Snisarenko
Independent Director
Mary Szela
No Data
About ALIM
Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through U.S. and International segment. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, Canada, Lebanon and the United Arab Emirates, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

Webull offers kinds of Alimera Sciences Inc stock information, including NASDAQ:ALIM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALIM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALIM stock methods without spending real money on the virtual paper trading platform.